H S Süzen1, N Yüce, G Güvenç, Y Duydu, T Erke. 1. Department of Toxicology, Faculty of Pharmacy, Ankara University, 06100 Tandoğan, Ankara, Turkey. suzen@pharmacy.ankara.edu.tr
Abstract
OBJECTIVE: The thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) enzymes affect the outcome of 5-fluorouracil (5-FU)-based chemotherapy. Genetic polymorphisms of the thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) genes that may affect chemotherapy are described. The aim of this study was to determine the frequencies of TYMS and DPYD polymorphisms in healthy Turkish individuals. METHODS: Genotyping analyses of the promoter enhancer region of TYMS (TSER) and the exon 14-skipping mutation of the DPYD (DPYD*2A) genes were conducted in 250 unrelated, healthy volunteers from the central region of Turkey using a PCR-based assay. RESULTS: The distribution of the TSER*2/*2, *2/*3 and *3/*3 genotypes were 17.6%, 48.8%, and 33.6%, respectively. The frequencies of the TSER*2 and *3 alleles in the Turkish population were 0.42 and 0.58, respectively. No individuals with the variant DPYD*2A allele were identified in the study group. CONCLUSION: The frequency of the TSER*3 allele among members of the Turkish population was similar to frequencies observed in other Caucasian populations but was lower than those found in Japanese and Chinese populations.
OBJECTIVE: The thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) enzymes affect the outcome of 5-fluorouracil (5-FU)-based chemotherapy. Genetic polymorphisms of the thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) genes that may affect chemotherapy are described. The aim of this study was to determine the frequencies of TYMS and DPYD polymorphisms in healthy Turkish individuals. METHODS: Genotyping analyses of the promoter enhancer region of TYMS (TSER) and the exon 14-skipping mutation of the DPYD (DPYD*2A) genes were conducted in 250 unrelated, healthy volunteers from the central region of Turkey using a PCR-based assay. RESULTS: The distribution of the TSER*2/*2, *2/*3 and *3/*3 genotypes were 17.6%, 48.8%, and 33.6%, respectively. The frequencies of the TSER*2 and *3 alleles in the Turkish population were 0.42 and 0.58, respectively. No individuals with the variant DPYD*2A allele were identified in the study group. CONCLUSION: The frequency of the TSER*3 allele among members of the Turkish population was similar to frequencies observed in other Caucasian populations but was lower than those found in Japanese and Chinese populations.
Authors: E Villafranca; Y Okruzhnov; M A Dominguez; J García-Foncillas; I Azinovic; E Martínez; J J Illarramendi; F Arias; R Martínez Monge; E Salgado; S Angeletti; A Brugarolas Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: Vilmos Adleff; Erika Hitre; István Köves; Zsolt Orosz; Anna Hajnal; Judit Kralovánszky Journal: Int J Cancer Date: 2004-03-01 Impact factor: 7.396
Authors: Karen S Brown; Leo A J Kluijtmans; Ian S Young; Helene McNulty; Laura E Mitchell; John W G Yarnell; Jayne V Woodside; Colin A Boreham; Dorothy McMaster; Liam Murray; J J Strain; Alexander S Whitehead Journal: Hum Genet Date: 2003-10-25 Impact factor: 4.132
Authors: Rita de Cássia Carvalho Barbosa; Débora Costa Menezes; Thiago Fernando Vasconcelos Freire; Diogo Campos Sales; Victor Hugo Medeiros Alencar; Silvia Helena Barem Rabenhorst Journal: Mol Biol Rep Date: 2011-12-02 Impact factor: 2.316
Authors: Mohammad Hadi Abbasian; Nafiseh Ansarinejad; Bahareh Abbasi; Masoud Iravani; Tayeb Ramim; Fahime Hamedi; Ali M Ardekani Journal: Avicenna J Med Biotechnol Date: 2020 Jul-Sep